ArticleFrontiers in oncology2026
Efficacy and safety of stereotactic radiotherapy in patients with HER2-positive breast cancer brain metastases following intracranial oligoprogression.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tyrosine kinase inhibitors (TKIs) demonstrate clear therapeutic effects in patients with HER2-positive breast cancer complicated by brain metastases. However, the efficacy and safety of salvage stereotactic radiotherapy (SRT) for intracranial oligoprogression after TKI therapy remain unclear. This single-center retrospective cohort study aimed to evaluate the clinical value of SRT in this specific population, enrolling 40 HER2-positive breast cancer patients with brain metastases who received SRT for intracranial oligoprogression after TKI therapy at the Department of Radiotherapy, Fourth Hospital of Hebei Medical University between January 2020 and January 2025. Patients were stratified into the MRI-stable disease (SD) group and MRI-progressive disease (PD) group according to intracranial oligoprogression features. The main outcome measures included post-radiotherapy intracranial progression-free survival (poRT-iPFS), time to next systemic treatment (NEST), overall survival (OS), and treatment safety. The median follow-up duration was 10.7 months (interquartile range [IQR] 7.0-20.8 months), with a median poRT-iPFS of 6.4 months (95% confidence interval [CI] 6.3-8.3 months), median NEST of 5.2 months (95% CI 4.7-6.5 months), and median OS of 9.5 months (95% CI 8.6-10.6 months). Stratified analysis revealed a significantly longer median poRT-iPFS in the MRI-SD group than in the MRI-PD group (7.9 months, 95% CI 7.5-8.3 vs. 5.5 months, 95% CI 4.6-6.4; P < 0.001). The main grade ≥ 3 treatment-related adverse events (TEAEs) were diarrhoea (20%), anaemia (20%), leucopenia (18%), nausea (15%), and thrombocytopenia (13%); Only 2 patients (5%) developed grade 1 radiation necrosis, and no interstitial pneumonia was reported. In conclusion, SRT provides considerable survival benefits and a manageable safety profile for HER2-positive breast cancer patients with brain metastases who develop intracranial oligoprogression after TKI therapy. MRI-stable intracranial lesions accompanied by increased peritumoural oedema may serve as a valuable indicator for initiating proactive radiotherapy intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.